Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Benefits and drawbacks of statins and non-statin lipid lowering agents in carotid artery disease.
Paraskevas KI, Gloviczki P, Antignani PL, Comerota AJ, Dardik A, Davies AH, Eckstein HH, Faggioli G, Fernandes E Fernandes J, Fraedrich G, Geroulakos G, Golledge J, Gupta A, Gurevich VS, Jawien A, Jezovnik MK, Kakkos SK, Knoflach M, Lanza G, Liapis CD, Loftus IM, Mansilha A, Nicolaides AN, Pini R, Poredos P, Proczka RM, Ricco JB, Rundek T, Saba L, Schlachetzki F, Silvestrini M, Spinelli F, Stilo F, Suri JS, Svetlikov AV, Zeebregts CJ, Chaturvedi S, Veith FJ, Mikhailidis DP. Paraskevas KI, et al. Among authors: gurevich vs. Prog Cardiovasc Dis. 2022 Jul-Aug;73:41-47. doi: 10.1016/j.pcad.2022.05.003. Epub 2022 May 20. Prog Cardiovasc Dis. 2022. PMID: 35605696 Review.
[Inclisiran - a new era in lipid-lowering therapy].
Voevoda MI, Gurevich VS, Ezhov MV, Sergienko IV. Voevoda MI, et al. Among authors: gurevich vs. Kardiologiia. 2022 Jun 30;62(6):57-62. doi: 10.18087/cardio.2022.6.n2115. Kardiologiia. 2022. PMID: 35834343 Russian.
Statins and autoimmune diseases.
Gurevich VS, Shovman O, Slutzky L, Meroni PL, Shoenfeld Y. Gurevich VS, et al. Autoimmun Rev. 2005 Mar;4(3):123-9. doi: 10.1016/j.autrev.2004.08.037. Autoimmun Rev. 2005. PMID: 15823497 Review.
[Possibilities of clinical use of ezetimibe Otrio (JSC "AKRIKHIN", Russia) in patients with high and very high cardiovascular risk who have not reached the target values of lipid metabolism. Conclusion of the Board of experts].
Kobalava JD, Gurevich VS, Galyavich AM, Kaminnyi AI, Kashtalap VV, Mareev VY, Susekov AV, Shaposhnik II. Kobalava JD, et al. Among authors: gurevich vs. Kardiologiia. 2019 Jun 20;59(5S):47-57. doi: 10.18087/cardio.n581. Kardiologiia. 2019. PMID: 31221075 Russian.
[Improvement of outcomes in patients with recent acute coronary syndrome: the place of PCSK9 inhibitors. The Resolution of National Advisory Board].
Akhmedzhanov NM, Vezikova NN, Voevoda MI, Galyavich AS, Gurevich VS, Duplyakov DV, Ezhov MV, Karpov YA, Kashtalap VV, Konovalov GA, Smolenskaya OG, Yakovlev AN. Akhmedzhanov NM, et al. Among authors: gurevich vs. Kardiologiia. 2019 Jun 20;59(5S):58-64. doi: 10.18087/cardio.n308. Kardiologiia. 2019. PMID: 31221076 Russian.
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Hagström E, Steg PG, Szarek M, Bhatt DL, Bittner VA, Danchin N, Diaz R, Goodman SG, Harrington RA, Jukema JW, Liberopoulos E, Marx N, McGinniss J, Manvelian G, Pordy R, Scemama M, White HD, Zeiher AM, Schwartz GG; ODYSSEY OUTCOMES Investigators. Hagström E, et al. Circulation. 2022 Aug 30;146(9):657-672. doi: 10.1161/CIRCULATIONAHA.121.057807. Epub 2022 Jun 30. Circulation. 2022. PMID: 35770629 Free PMC article. Clinical Trial.
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators. Schwartz GG, et al. N Engl J Med. 2018 Nov 29;379(22):2097-2107. doi: 10.1056/NEJMoa1801174. Epub 2018 Nov 7. N Engl J Med. 2018. PMID: 30403574 Free article. Clinical Trial.
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.
Schwartz GG, Szarek M, Bittner VA, Diaz R, Goodman SG, Jukema JW, Landmesser U, López-Jaramillo P, Manvelian G, Pordy R, Scemama M, Sinnaeve PR, White HD, Gabriel Steg P; ODYSSEY Outcomes Committees and Investigators. Schwartz GG, et al. J Am Coll Cardiol. 2021 Aug 3;78(5):421-433. doi: 10.1016/j.jacc.2021.04.102. J Am Coll Cardiol. 2021. PMID: 34325831 Free PMC article. Clinical Trial.
72 results